[1]郭莲,张先祥.Graves病患者131I治疗前后血清TNF-α和TRAb水平的变化及其相关性研究[J].陆军军医大学学报(原第三军医大学学报),2013,35(14):1528-1530.
 Guo Lian,Zhang Xianxiang.Changes and correlation of serum levels of TNF-α and TRAb in patients with Graves’ disease before and after 131I treatment[J].J Amry Med Univ (J Third Mil Med Univ),2013,35(14):1528-1530.
点击复制

Graves病患者131I治疗前后血清TNF-α和TRAb水平的变化及其相关性研究(/HTML )
分享到:

陆军军医大学学报(原第三军医大学学报)[ISSN:1000-5404/CN:51-1095/R]

卷:
35卷
期数:
2013年第14期
页码:
1528-1530
栏目:
论著
出版日期:
2013-07-30

文章信息/Info

Title:
Changes and correlation of serum levels of TNF-α and TRAb in patients with Graves’ disease before and after 131I treatment
作者:
郭莲张先祥
重庆三峡中心医院内分泌科
Author(s):
Guo Lian Zhang Xianxiang
Department of Endocrinology, Chongqing Three Gorges Central Hospital, Chongqing, 404000, China
关键词:
Graves病131I治疗TNF-αTRAb
Keywords:
Graves’ disease 131I treatment TNF-α anti-hyrotropin receptor antibody
分类号:
R392.11;R446.1;R581.1
文献标志码:
A
摘要:
目的      观察Graves病患者131I治疗前后血清肿瘤坏死因子-α(TNF-α)和促甲状腺激素受体抗体(TRAb)的变化,探讨TNF-α、TRAb与Graves病发病的关系。      方法      设120例行131I治疗的Graves病患者作为治疗组,其中男性22例,女性98例,年龄(32±12)岁。取60例同期体检合格的健康人作为对照组,其中男性35例,女性25例,年龄(34±11)岁。采用化学发光法(ECLIA)、流式细胞法(FCM)检测2组治疗前及治疗后3、6、18个月的FT3、FT4、TSH、TRAb、TNF-α水平,并进行对比分析。      结果      与对照组比较,治疗组治疗前,FT3、FT4、TRAb、TNF-α均有明显升高,TSH明显降低,治疗后3、6、18个月各指标逐渐改善,均有显著差异(P<0.05);治疗后18个月FT3、FT4、TSH指标[分别为(4.61±0.87)pmol/L、(15.71±5.22)pmol/L,(2.89±0.62)μIU/L]接近对照组水平,差异无统计学意义(P>0.05),TNF-α、TRAb[(2.42±1.22)pg/mL,(18.27±1.53)IU/mL]高于对照组水平,差异有统计学意义(P<0.05);治疗组治疗前及治疗后3、6、18个月TNF-α、TRAb水平呈显著正相关(r=0.883、0.791、0.815、0.742,P<0.05)。      结论      TNF-α和TRAb在Graves病患者中高表达,并呈显著正相关,在Graves病的发生、发展中起着重要作用。
Abstract:
Objective      To explore the changes and correlation of serum levels of tumor necrosis factor-α(TNF-α)and anti-hyrotropin receptor antibody (TRAb) in patients with Graves’ disease before and after 131I treatment, and investigate the roles of TNF-α and TRAb in the incidence of Graves’ disease.       Methods      Clinical data of 120 patients who diagnosed with Graves’ disease and treated with 131I in our department from October 2009 to October 2011 were collected in this study. They were 22 males and 98 females, with an average age of 32±12. Sixty age- and sex-matched healthy subjects served as control. Serum levels of FT3, FT4, TSH, TRAb and TNF-α in control group and treatment group before and in 3, 6 and 18 months after treatment were measured by using electrochemical luminescence immunoassay (ECLIA) and flow cytometry (FCM). The results were compared between the 2 groups.       Results      Serum levels of FT3, FT4, TRAb and TNF-α were significantly higher, while that of TSH was significantly lower in the treatment group before treatment than in the control (P<0.05). In 3, 6 and 18 months after treatment, the above mentioned indexes were obviously improved (P<0.05). In 18 months after treatment, the levels of FT3 (4.61±0.87 pmol/L), FT4 (15.71±5.22 pmol/L) and TSH (2.89±0.62 μIU/L) in treatment group were almost close to those of control (P>0.05), but those of TNF-α (2.42±1.22 pg/mL) and TRAb (18.27±1.53 IU/mL) were significantly higher than those of the control group (P<0.05). The serum level of TNF-α was positively correlated with that of TRAb before and in 3, 6 and 18 months after treatment (P<0.05).       Conclusion      TNF-α and TRAb are highly expressed and positively correlated in the serum of the patients with Graves’ disease, and play important roles in the incidence and development of the disease.

相似文献/References:

[1]罗朝学,黄定德,刘开元,等.131I治疗303例Graves病早期变化分析[J].陆军军医大学学报(原第三军医大学学报),2007,29(07):635.
 LUO Chao-xue,HUANG Ding-de,LIU Kai-yuan,et al.Inchoate changes in 303 cases of Graves disease treated with 131I[J].J Amry Med Univ (J Third Mil Med Univ),2007,29(14):635.
[2]王燕,朱中桃.肝豆状核变性合并Graves病周期性麻痹1例[J].陆军军医大学学报(原第三军医大学学报),2010,32(04):407.
[3]杨士军,崔兆辉,陆卫平.Graves病患者血清Ghrelin水平与甲状腺功能状态的关系[J].陆军军医大学学报(原第三军医大学学报),2010,32(24):2668.
[4]黎南中,文玉梅,程时武,等.Graves病、黑棘皮病合并B型胰岛素抵抗综合征1例[J].陆军军医大学学报(原第三军医大学学报),2011,33(02):189.
[5]肖蓉,黄和银,周泽华,等.Graves病患者心率变异性分析[J].陆军军医大学学报(原第三军医大学学报),2003,25(17):0.[doi:10.16016/j.1000-5404.2003.17.013 ]
[6]吴平,李华,易吉秀,等.2种剂量131I治疗Graves病的前瞻性随机对照研究[J].陆军军医大学学报(原第三军医大学学报),2012,34(16):1677.
 Wu Ping,Li Hua,Yi Jimei,et al.Therapeutic effect of 131-iodine at 2 different doses for Graves’ disease: a randomized controlled trial[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(14):1677.
[7]江学容,谭兴容,鲁远彪,等.131I治疗Graves病的远期效果随访研究[J].陆军军医大学学报(原第三军医大学学报),2012,34(16):1689.

更新日期/Last Update: 2013-07-10